• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

胃癌中脂质代谢与免疫浸润特征之间的相关性进展以及将BCHE鉴定为潜在生物标志物

Progressions of the correlation between lipid metabolism and immune infiltration characteristics in gastric cancer and identification of BCHE as a potential biomarker.

作者信息

Wang Shibo, Huang Xiaojuan, Zhao Shufen, Lv Jing, Li Yi, Wang Shasha, Guo Jing, Wang Yan, Wang Rui, Zhang Mengqi, Qiu Wensheng

机构信息

Department of Oncology, The Affiliated Hospital of Qingdao University, Qingdao, China.

Department of Dermatology, The Affiliated Hospital of Qingdao University, Qingdao, China.

出版信息

Front Immunol. 2024 Jan 31;15:1327565. doi: 10.3389/fimmu.2024.1327565. eCollection 2024.

DOI:10.3389/fimmu.2024.1327565
PMID:38357546
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10864593/
Abstract

BACKGROUND

Globally, gastric cancer (GC) is a category of prevalent malignant tumors. Its high occurrence and fatality rates represent a severe threat to public health. According to recent research, lipid metabolism (LM) reprogramming impacts immune cells' ordinary function and is critical for the onset and development of cancer. Consequently, the article conducted a sophisticated bioinformatics analysis to explore the potential connection between LM and GC.

METHODS

We first undertook a differential analysis of the TCGA queue to recognize lipid metabolism-related genes (LRGs) that are differentially expressed. Subsequently, we utilized the LASSO and Cox regression analyses to create a predictive signature and validated it with the GSE15459 cohort. Furthermore, we examined somatic mutations, immune checkpoints, tumor immune dysfunction and exclusion (TIDE), and drug sensitivity analyses to forecast the signature's immunotherapy responses.

RESULTS

Kaplan-Meier (K-M) curves exhibited considerably longer OS and PFS (p<0.001) of the low-risk (LR) group. PCA analysis and ROC curves evaluated the model's predictive efficacy. Additionally, GSEA analysis demonstrated that a multitude of carcinogenic and matrix-related pathways were much in the high-risk (HR) group. We then developed a nomogram to enhance its clinical practicality, and we quantitatively analyzed tumor-infiltrating immune cells (TIICs) using the CIBERSORT and ssGSEA algorithms. The low-risk group has a lower likelihood of immune escape and more effective in chemotherapy and immunotherapy. Eventually, we selected BCHE as a potential biomarker for further research and validated its expression. Next, we conducted a series of cell experiments (including CCK-8 assay, Colony formation assay, wound healing assay and Transwell assays) to prove the impact of BCHE on gastric cancer biological behavior.

DISCUSSION

Our research illustrated the possible consequences of lipid metabolism in GC, and we identified BCHE as a potential therapeutic target for GC. The LRG-based signature could independently forecast the outcome of GC patients and guide personalized therapy.

摘要

背景

在全球范围内,胃癌(GC)是一类常见的恶性肿瘤。其高发病率和死亡率对公众健康构成严重威胁。根据最近的研究,脂质代谢(LM)重编程会影响免疫细胞的正常功能,对癌症的发生和发展至关重要。因此,本文进行了深入的生物信息学分析,以探索LM与GC之间的潜在联系。

方法

我们首先对TCGA队列进行差异分析,以识别差异表达的脂质代谢相关基因(LRGs)。随后,我们利用LASSO和Cox回归分析创建了一个预测特征,并在GSE15459队列中进行了验证。此外,我们还进行了体细胞突变、免疫检查点、肿瘤免疫功能障碍和排除(TIDE)以及药物敏感性分析,以预测该特征的免疫治疗反应。

结果

Kaplan-Meier(K-M)曲线显示低风险(LR)组的总生存期(OS)和无进展生存期(PFS)明显更长(p<0.001)。主成分分析(PCA)和ROC曲线评估了模型的预测效能。此外,基因集富集分析(GSEA)表明,许多致癌和基质相关通路在高风险(HR)组中更为活跃。然后,我们开发了一个列线图以提高其临床实用性,并使用CIBERSORT和ssGSEA算法对肿瘤浸润免疫细胞(TIICs)进行了定量分析。低风险组免疫逃逸的可能性较低,在化疗和免疫治疗中更有效。最终,我们选择丁酰胆碱酯酶(BCHE)作为潜在的生物标志物进行进一步研究,并验证了其表达。接下来,我们进行了一系列细胞实验(包括CCK-8检测、集落形成检测、伤口愈合检测和Transwell检测),以证明BCHE对胃癌生物学行为的影响。

讨论

我们的研究阐明了脂质代谢在GC中的可能影响,并且我们确定BCHE为GC的潜在治疗靶点。基于LRG的特征可以独立预测GC患者的预后并指导个性化治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/609a/10864593/bdc1d0dc2f35/fimmu-15-1327565-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/609a/10864593/335933ceb66d/fimmu-15-1327565-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/609a/10864593/8d750e82b1aa/fimmu-15-1327565-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/609a/10864593/1c10fddbc665/fimmu-15-1327565-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/609a/10864593/79fc7ee3e256/fimmu-15-1327565-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/609a/10864593/673e1d0aeca4/fimmu-15-1327565-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/609a/10864593/ed67bd6547fb/fimmu-15-1327565-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/609a/10864593/dfef5c75ffad/fimmu-15-1327565-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/609a/10864593/00c9730cf487/fimmu-15-1327565-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/609a/10864593/091a1fb5ec1f/fimmu-15-1327565-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/609a/10864593/b3ff9f8cea3e/fimmu-15-1327565-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/609a/10864593/80ee42acbaef/fimmu-15-1327565-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/609a/10864593/e488c00f876b/fimmu-15-1327565-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/609a/10864593/bdc1d0dc2f35/fimmu-15-1327565-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/609a/10864593/335933ceb66d/fimmu-15-1327565-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/609a/10864593/8d750e82b1aa/fimmu-15-1327565-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/609a/10864593/1c10fddbc665/fimmu-15-1327565-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/609a/10864593/79fc7ee3e256/fimmu-15-1327565-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/609a/10864593/673e1d0aeca4/fimmu-15-1327565-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/609a/10864593/ed67bd6547fb/fimmu-15-1327565-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/609a/10864593/dfef5c75ffad/fimmu-15-1327565-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/609a/10864593/00c9730cf487/fimmu-15-1327565-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/609a/10864593/091a1fb5ec1f/fimmu-15-1327565-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/609a/10864593/b3ff9f8cea3e/fimmu-15-1327565-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/609a/10864593/80ee42acbaef/fimmu-15-1327565-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/609a/10864593/e488c00f876b/fimmu-15-1327565-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/609a/10864593/bdc1d0dc2f35/fimmu-15-1327565-g013.jpg

相似文献

1
Progressions of the correlation between lipid metabolism and immune infiltration characteristics in gastric cancer and identification of BCHE as a potential biomarker.胃癌中脂质代谢与免疫浸润特征之间的相关性进展以及将BCHE鉴定为潜在生物标志物
Front Immunol. 2024 Jan 31;15:1327565. doi: 10.3389/fimmu.2024.1327565. eCollection 2024.
2
A novel copper-induced cell death-related lncRNA prognostic signature associated with immune infiltration and clinical value in gastric cancer.一种新型铜诱导细胞死亡相关 lncRNA 预后标志物与胃癌免疫浸润和临床价值相关。
J Cancer Res Clin Oncol. 2023 Sep;149(12):10543-10559. doi: 10.1007/s00432-023-04916-7. Epub 2023 Jun 8.
3
A nomogram model based on the number of examined lymph nodes-related signature to predict prognosis and guide clinical therapy in gastric cancer.基于检查淋巴结数量相关特征的列线图模型预测胃癌的预后并指导临床治疗。
Front Immunol. 2022 Nov 2;13:947802. doi: 10.3389/fimmu.2022.947802. eCollection 2022.
4
HIGD1B, as a novel prognostic biomarker, is involved in regulating the tumor microenvironment and immune cell infiltration; its overexpression leads to poor prognosis in gastric cancer patients.HIGD1B 作为一种新型的预后生物标志物,参与调节肿瘤微环境和免疫细胞浸润;其过表达导致胃癌患者预后不良。
Front Immunol. 2024 Jul 23;15:1415148. doi: 10.3389/fimmu.2024.1415148. eCollection 2024.
5
A novel signature incorporating lipid metabolism- and immune-related genes to predict the prognosis and immune landscape in hepatocellular carcinoma.一种包含脂质代谢和免疫相关基因的新型特征,用于预测肝细胞癌的预后和免疫格局。
Front Oncol. 2023 Jun 6;13:1182434. doi: 10.3389/fonc.2023.1182434. eCollection 2023.
6
Identification of a six-gene signature to predict survival and immunotherapy effectiveness of gastric cancer.用于预测胃癌生存及免疫治疗疗效的六基因特征识别
Front Oncol. 2023 Jun 19;13:1210994. doi: 10.3389/fonc.2023.1210994. eCollection 2023.
7
Identification of a basement membrane-related genes signature to predict prognosis, immune landscape and guide therapy in gastric cancer.鉴定与基底膜相关的基因特征,以预测胃癌的预后、免疫图谱并指导治疗。
Medicine (Baltimore). 2023 Sep 29;102(39):e35027. doi: 10.1097/MD.0000000000035027.
8
Development and validation of a novel lipid metabolism-related gene prognostic signature and candidate drugs for patients with bladder cancer.开发和验证一种新型的与脂质代谢相关的基因预后标志物,并为膀胱癌患者找到候选药物。
Lipids Health Dis. 2021 Oct 27;20(1):146. doi: 10.1186/s12944-021-01554-1.
9
Tumor microenvironment characteristics of lipid metabolism reprogramming related to ferroptosis and EndMT influencing prognosis in gastric cancer.胃癌中与铁死亡和 EndMT 相关的脂质代谢重编程的肿瘤微环境特征影响预后。
Int Immunopharmacol. 2024 Aug 20;137:112433. doi: 10.1016/j.intimp.2024.112433. Epub 2024 Jun 12.
10
Lipid Metabolic-Related Signature CYP19A1 is a Potential Biomarker for Prognosis and Immune Cell Infiltration in Gastric Cancer.脂质代谢相关标志物CYP19A1是胃癌预后和免疫细胞浸润的潜在生物标志物。
J Inflamm Res. 2022 Sep 5;15:5075-5088. doi: 10.2147/JIR.S378212. eCollection 2022.

引用本文的文献

1
Lipid Metabolism Reprogramming in Cancer: Insights into Tumor Cells and Immune Cells Within the Tumor Microenvironment.癌症中的脂质代谢重编程:对肿瘤微环境中肿瘤细胞和免疫细胞的见解
Biomedicines. 2025 Aug 4;13(8):1895. doi: 10.3390/biomedicines13081895.
2
A New Medical Evaluation for Gastric Cancer Patients to Increase the Success Rate of Immunotherapy: A 2024 Update.一种提高胃癌患者免疫治疗成功率的新医学评估:2024年更新
Pharmaceuticals (Basel). 2024 Aug 24;17(9):1121. doi: 10.3390/ph17091121.
3
HIGD1B, as a novel prognostic biomarker, is involved in regulating the tumor microenvironment and immune cell infiltration; its overexpression leads to poor prognosis in gastric cancer patients.

本文引用的文献

1
Design, Synthesis, and Proof of Concept of Balanced Dual Inhibitors of Butyrylcholinesterase (BChE) and Histone Deacetylase 6 (HDAC6) for the Treatment of Alzheimer's Disease.设计、合成及双靶点丁酰胆碱酯酶(BChE)和组蛋白去乙酰化酶 6(HDAC6)抑制剂用于阿尔茨海默病治疗的概念验证。
ACS Chem Neurosci. 2023 Sep 6;14(17):3226-3248. doi: 10.1021/acschemneuro.3c00358. Epub 2023 Aug 10.
2
Targeting inhibition of prognosis-related lipid metabolism genes including CYP19A1 enhances immunotherapeutic response in colon cancer.靶向抑制预后相关脂质代谢基因,包括 CYP19A1,可增强结肠癌的免疫治疗反应。
J Exp Clin Cancer Res. 2023 Apr 13;42(1):85. doi: 10.1186/s13046-023-02647-8.
3
HIGD1B 作为一种新型的预后生物标志物,参与调节肿瘤微环境和免疫细胞浸润;其过表达导致胃癌患者预后不良。
Front Immunol. 2024 Jul 23;15:1415148. doi: 10.3389/fimmu.2024.1415148. eCollection 2024.
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth.
不断演变的肿瘤微环境:从癌症起始到转移灶生长
Cancer Cell. 2023 Mar 13;41(3):374-403. doi: 10.1016/j.ccell.2023.02.016.
4
The Role of PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma Metabolism.PI3K/AKT/mTOR 信号通路在肝癌代谢中的作用。
Int J Mol Sci. 2023 Jan 31;24(3):2652. doi: 10.3390/ijms24032652.
5
Characterization of lipid droplet metabolism patterns identified prognosis and tumor microenvironment infiltration in gastric cancer.脂质滴代谢模式的特征鉴定了胃癌的预后和肿瘤微环境浸润。
Front Oncol. 2023 Jan 11;12:1038932. doi: 10.3389/fonc.2022.1038932. eCollection 2022.
6
The role of lipids in cancer progression and metastasis.脂质在癌症进展和转移中的作用。
Cell Metab. 2022 Nov 1;34(11):1675-1699. doi: 10.1016/j.cmet.2022.09.023. Epub 2022 Oct 18.
7
Cuproptosis regulator-mediated patterns associated with immune infiltration features and construction of cuproptosis-related signatures to guide immunotherapy.铜死亡调控因子相关模式与免疫浸润特征相关,并构建铜死亡相关特征以指导免疫治疗。
Front Immunol. 2022 Sep 29;13:945516. doi: 10.3389/fimmu.2022.945516. eCollection 2022.
8
Lipid Metabolic-Related Signature CYP19A1 is a Potential Biomarker for Prognosis and Immune Cell Infiltration in Gastric Cancer.脂质代谢相关标志物CYP19A1是胃癌预后和免疫细胞浸润的潜在生物标志物。
J Inflamm Res. 2022 Sep 5;15:5075-5088. doi: 10.2147/JIR.S378212. eCollection 2022.
9
BCHE as a Prognostic Biomarker in Endometrial Cancer and Its Correlation with Immunity.BCHE 作为子宫内膜癌的预后生物标志物及其与免疫的相关性。
J Immunol Res. 2022 Jul 21;2022:6051092. doi: 10.1155/2022/6051092. eCollection 2022.
10
STARD5 as a potential clinical target of hepatocellular carcinoma.STARD5 作为肝细胞癌的潜在临床靶点。
Med Oncol. 2022 Jul 19;39(10):156. doi: 10.1007/s12032-022-01750-8.